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Abstract: Breast milk contains immunomodulating components that are beneficial to newborns
during maturation of their immune system. Human breast milk composition is influenced by an
infant’s gestational and chronological age, lactation stage, and the mother and infant’s health status.
Major immunologic components in human milk, such as secretory immunoglobulin A (IgA) and
growth factors, have a known role in regulating gut barrier integrity and microbial colonization,
which therefore protect against the development of a life-threatening gastrointestinal illness affecting
newborn infants called necrotizing enterocolitis (NEC). Breast milk is a known protective factor in the
prevention of NEC when compared with feeding with commercial formula. Breast milk supplements
infants with human milk oligosaccharides, leukocytes, cytokines, nitric oxide, and growth factors
that attenuate inflammatory responses and provide immunological defenses to reduce the incidence
of NEC. This article aims to review the variety of immunomodulating components in breast milk that
protect the infant from the development of NEC.
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1. Introduction
Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease in preterm infants with
associated mortality as high as 50% in cases that require surgical intervention [1]. NEC occurs in 1–5%
of patients admitted to a neonatal intensive care unit (NICU), and increased incidence and fatality
occurs in infants with prematurity and low birth weight [2]. The etiology of NEC is complex, and
pathogenesis is attributed to inflammation of the neonatal gastrointestinal tract by triggers such as
commercial formula feeds, intestinal dysbiosis, and immaturity of gut mucosal immunity. Treatment
of NEC requires withholding enteral feeds and potent antimicrobial agents, and these infants are
at risk of adverse long term outcomes. Identification of factors that contribute to the prevention of
NEC remains a high priority in neonatal research. There is a consensus regarding the protective
nature of breast milk in the prevention of NEC development. Human breast milk, in contrast to
commercial formulas, contains soluble and cellular components that provide infants with passive
immunity to their gastrointestinal tract. These antimicrobial and bioactive factors are multi-functional
and anti-inflammatory, with an established protective role against the development of NEC. An early
prospective study of 926 infants showed that exclusively formula-fed preterm infants were six to ten
times more likely to acquire NEC as compared to preterm infants nourished with human milk alone [3].
Furthermore, an analysis of 243 infants in a randomized trial showed that preterm infants less than 30
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weeks’ gestation who received maternal milk had reduced incidence of late-onset sepsis or NEC as
compared with preterm infants who received donor breast milk or commercial formula [4]. Sullivan
and colleagues demonstrated in a randomized, controlled, multicenter trial that extremely premature
infants who received only human milk, including human milk-derived fortification, had decreased
rates of NEC compared to those infants exposed to bovine milk-derived products with a number
needed to treat of 10 infants to prevent one NEC case [5].
Breast milk composition is complex, dynamic, and influenced by a variety of maternal factors.
Immunoglobulins, antimicrobial peptides, growth factors, human milk oligosaccharides, cytokines,
L-glutamine, and nitric oxide in breast milk maintain roles in the enhancement of the neonatal intestinal
barrier function and the reduction of NEC. This article aims to review the protective role of breast milk
and its components against NEC, as shown in Figure 1.
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2. Breast Milk and the Host-Microbial Relationship
2.1. Maternal Soluble IgA
Bioactive components of maternal milk, particularly immunoglobulin A (IgA), have known
influenti l effects on the neonatal microbiota. IgA is the most plentiful antibody in human milk
and comprises a significant portion of total protein content in colostrum [6]. IgA produced by the
maternal mammary glands undergoes proteolytic cleavage to release secretory IgA (sIgA), permitting
transport into human milk [7]. Breast milk sIgA provides critical antimicrobial defense to the neonatal
gastrointestinal tract through inhibition of pathogen attachment to mucosal surfaces, neutralization of
microbial toxins, and provision of passive immunity. IgM and IgG are of lesser abundance in human
milk but also have known immune-surveillance properties.
The sIgA levels in breast milk decrease over time during the postpartum period [8]. Recent studies
have identified no difference in breast milk sIgA concentration of preterm versus term breast milk [6,8],
although Mehta and Petrova identified that preterm milk contains a higher concentration of sIgA
in the first six to eight days of lactation [9]. Breast milk sIgA is a critical component, as it promotes
colonization of commensal microbiota, decreasing the activity of pattern recognition receptors and
subsequent downstream inflammation within the intestinal epithelium [10]. A humoral response with
increased levels of sIgA in mature breast milk has been shown to occur in response to an infection in
the mother or infant [11]. Gopalakrishna and colleagues studied the role that sIgA in breast milk plays
in the pathogenesis of NEC [12]. They determined the proportion of IgA-associated intestinal bacteria
and discovered that premature infants with an exclusive formula-fed diet contained very low levels of
IgA-associated intestinal bacteria. Furthermore, infants with NEC had higher levels of IgA-unbound
Enterobacteriaceae when compared with healthy age-matched controls. This suggests that insufficient
concentrations of IgA and decreased IgA-bound bacteria in the intestine may be causative factors of
Nutrients 2020, 12, 14 3 of 14
insufficient microbiome diversity and increased risk of NEC development [12]. In a neonatal mouse
model of NEC, pups reared by IgA-deficient mothers showed susceptibility to intestinal disease despite
receiving maternal milk, suggesting that maternal IgA can define the host-microbiota relationship and
underscoring that the IgA in milk plays an important role in the susceptibility to NEC [12].
2.2. Lactoferrin
Lactoferrin is an abundant peptide in human milk and has known roles in host defense and
antimicrobial properties. When lactoferrin encounters proteolysis in acidic conditions, such as in
the stomach, lactoferricin is produced. Lactoferricin has both strong antibacterial and some antiviral
activity with immunomodulatory capabilities [13]. In particular, human lactoferricin has a potent
ability to neutralize endotoxin activity, prevent activation of mononuclear cells, and ultimately prevent
the secretion of cytokines, such as interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and IL-8, that
contribute to inflammation [13,14]. Togawa and colleagues demonstrated that the administration of
enteral lactoferrin in rats attenuated colonic inflammation after induction of colitis [15]. Many studies
have subsequently evaluated the modulatory role of lactoferrin in antimicrobial and immunological
defenses in infants. A Cochrane Review of six, small, randomized control trials (RCT) that provided
lactoferrin supplementation to enteral feeds found decreased late-onset bacterial and fungal sepsis in
preterm infants, although the evidence was identified as low in quality [16]. A systematic review and
meta-analysis reviewed nine RCTs and showed that prophylactic lactoferrin significantly reduced the
incidence of late-onset sepsis and NEC (Bell’s stage II or greater) [17]. Most recently, a large randomized
control trial of 2203 infants contrasted these prior findings, demonstrating that enteral supplementation
with bovine lactoferrin did not reduce NEC or the incidence of infection or mortality [18].
2.3. Lysozyme
Lysozyme, as an immune-active enzyme in colostrum and breast milk, has many bactericidal
effects. In synergy with lactoferrin, lysozyme can bind to lipopolysaccharide (LPS) on outer bacterial
membranes, which provides lysozyme access to degrade internal proteoglycan matrices of bacterial
membranes. Studies of breast milk composition have shown that premature breast milk as compared to
term breast milk has higher lysozyme content [6,9], although other studies have found no difference [8].
In the gastrointestinal tract, Paneth cells within the crypts of Lieberkühn produce a variety of
antimicrobial peptides, including lysozyme, which are secreted in response to enteric pathogens [19].
Of relevance to NEC, in the small intestinal biopsies of premature infants with NEC, there were
decreased concentrations of Paneth cells compared to controls [20]. The role of lysozyme has been
studied in a mouse model of NEC utilizing Paneth cell ablation. This model consists of 14-day-old
pups treated with dithizone, a heavy metal chelator, followed by luminal infection with Klebsiella [21].
The pups in this experimental group developed a NEC-like injury, suggesting the significance of
lysozyme and antimicrobial protection provided by Paneth cells can regulate the inflammatory response
in NEC [21]. A subsequent study using an experimental murine NEC model demonstrated that Paneth
cell deficiency induces a disruption in the intestinal microbiome, and in particular, the development of
an Enterobacteriaceae bloom, which has been shown to precede NEC in humans [22]. These results
signify the potential significance of breast milk lysozyme in protecting breast fed infants from the
intestinal inflammatory insult seen in NEC.
2.4. Lactadherin
Lactadherin (milk fat globule-epidermal growth factor (EGF) factor VIII) is a human milk
glycoprotein that contributes to apoptotic cell phagocytosis [23]. A deficiency of lactadherin has
been strongly associated with inflammatory and autoimmune diseases and has been shown to
maintain homeostasis of the intestinal epithelium through the migration of epithelial cells. In a
model of seven-week-old mice, treatment with recombinant lactadherin resulted in protection from
colitis, as demonstrated by downregulation of pro-inflammatory cytokines and improved histological
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scores [23]. Additionally, in a neonatal rat model of NEC-like intestinal injury, supplementation with
recombinant human lactadherin attenuated the disruption of cellular tight junctions [24].
2.5. Epidermal Growth Factor
The growth factors in breast milk serve a protective role in helping to facilitate the intestinal
mucosal barrier maturation. Maternal milk and colostrum contain epidermal growth factor (EGF) and
are the predominant sources of intestinal EGF during the postnatal phase. The roles of EGF in the
development of the intestine, as well as the response and repair of the intestine during intestinal injury
or infection, have been reported [25]. EGF levels are decreased in the saliva and serum of premature
infants with NEC when compared to infants without NEC. In a study of salivary EGF, infants with
NEC had lower salivary EGF in the first week after birth and greater increases from week of life one to
two as compared to infants without NEC, suggesting that NEC development may be attributed to
overall lower EGF concentrations in the at-risk neonate [26]. EGF also has proposed effects on goblet
cells and the production of mucin in the intestinal epithelium. Clark and colleagues showed that
treatment with EGF resulted in an increased number of goblet cells and increased the production of
mucin in the small intestine [27].
NEC has been associated with impaired intestinal barrier function and epithelial cell apoptosis.
The in vivo treatment with enteral EGF has shown to regulate the expression of tight junction proteins,
occludin and claudin-3 as well as normalize their expression at the site of NEC injury, helping to
maintain the gut barrier [27]. Additionally, enteral EGF administration can increase expression of
the anti-apoptotic protein, Bcl-2, and decrease levels of the pro-apoptotic protein, Bax. The role of
EGF in balancing apoptosis regulators provides implications of an opportunity for future therapeutic
strategies to protect the intestinal barrier from injury in NEC [28,29].
2.6. Heparin-Binding Epidermal Growth Factor
The developing fetus and the breast fed newborn are continually exposed to Heparin-binding
epidermal growth factor (HB-EGF), which is present in both amniotic fluid and breast milk, suggesting
its possible role in gastrointestinal epithelium development both in utero and during the neonatal
period [30]. As a member of the EGF family, HB-EGF binds to the EGF receptor (EGFR) and has known
mitogenic effects. HB-EGF is expressed in response to hypoxia, tissue damage, and oxidative stress,
including in the intestine, and has a pivotal role in tissue regeneration and repair [31,32]. In seeking to
evaluate the role of exogenous HB-EGF in the context of NEC, Dvorak and colleagues demonstrated
that either the oral administration of HB-EGF or EGF significantly reduced NEC in a premature rat
model through increased production of MUC2, a secretory mucin [33]. However, the concurrent
administration of both growth factors did not confer better protection and physiologic doses of EGF
provided better protection [33]. In another study, enteral administration of HB-EGF to neonatal rat pups
decreased the incidence and severity of NEC and reduced intestinal permeability as demonstrated by a
low serum concentration of enterally-administered fluorescein isothiocyanate-dextran [32]. The results
of these studies suggest a potential role of HB-EGF in the attenuation of intestinal injury during NEC.
2.7. Transforming Growth Factor-β2
Human milk contains high concentrations of the transforming growth factor-β isoform,
transforming growth factor-β2 (TGF-β2), which has immunomodulatory effects on intestinal
maturation, immunoglobulin production, and a suppressive effect on T cells [34]. Breast milk
with higher concentrations of TGF-β2 is associated with a higher diversity of intestinal microbial
composition in the neonate, a factor that is known to lower the risk of adult immunological diseases [34].
Of note, preterm human milk has been shown to have reduced TGF-β bioactivity [35]. Maheshwari
and colleagues analyzed TGF-β2 expression in premature infant intestinal tissue samples and observed
lower TGF-β2 expression and bioactivity in patients with NEC as compared with controls [36]. In a
murine experimental model of NEC, enterally administered recombinant TGF-β2 showed protective
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effects against NEC-like mucosal injury [36]. The addition of recombinant TGF-β2 to milk has
been investigated as a preventative strategy to boost the anti-inflammatory properties of milk and
prevent the development of NEC. However, it was discovered that in human preterm milk, TGF-β2 is
sequestered by chondroitin sulfate proteoglycans, which therefore inhibits its biological activity [35].
Consequently, the digestion of human preterm milk with chondroitinase resulted in the activation
of endogenous TGF-β2 and also restored the bioactivity of recombinant TGF-β2 [35]. These findings
suggest chondroitinase digestion of preterm milk may be an option for preventing NEC by enhancing
the anti-inflammatory properties of the milk.
2.8. Prebiotics and Oligosaccharides
Human milk oligosaccharides (HMOs) are complex sugars present in high abundance in breast
milk. HMOs serve as prebiotics and metabolic substrates with targeted antimicrobial activity, allowing
beneficial bacteria to thrive while suppressing those which are potentially harmful [37,38]. In an
in vitro epithelial model of the crypt-villus axis, treatment with HMOs resulted in reduced intestinal
cell proliferation, but promoted epithelial cell differentiation, indicating a potential role in intestinal
maturation [39].
HMOs ingested from breast milk undergo only minimal degradation in the infant’s acidic stomach
and by the pancreatic and brush border enzymes in order to reach the distal small intestine and
colon [37,38]. Preclinical animal studies as well as human studies in mother–infant dyads support
the contributions of HMOs in reduction of the development of NEC. In a cohort study comprised
of 200 mother–infant dyads, the composition of HMOs in breast milk was analyzed [40]. One
specific HMO, disialyllacto-N-tetraose (DSLNT) was identified to be present in significantly lower
concentrations in those infants who developed NEC [40]. Measurement of DSLNT levels in maternal
milk may therefore provide additional insight into why some breast fed infants are still at risk of NEC.
Enteral administration with supplemental HMOs have been studied as potential therapeutics
in reducing the risk of NEC [41,42]. For example, in a neonatal rat model of NEC, animals were fed
with DSLNT-containing formula, which resulted in reduced severity of NEC based on pathology
scores and improved survival [43]. The same study showed that galacto-oligosaccharides, an infant
formula additive, similar although structurally different from HMOs, demonstrated no effect on NEC
severity or survival in neonatal rats [43]. In a preterm pig model of NEC, receiving supplemental
feeds with a mixture of HMOs have not shown a significant difference in NEC severity, gut microbial
colonization, or intestinal permeability [42]. However, in a neonatal mouse model of NEC, enteral
administration of another HMO found in breast milk, 2’fucosyllactose (HMO-2’FL), resulted in the
preservation of mesenteric perfusion and restored the expression of endothelial nitric oxide synthase
(eNOS), a vasodilatory molecule necessary for intestinal perfusion [44]. The results of these studies
suggest key roles of HMO-2’FL and DSLNT as protective components of breast milk in the prevention
of NEC development.
2.9. Glutamine
Free amino acids comprise 3–5% of the total amino acids in human milk [45]. In a longitudinal
analysis of breast milk from healthy mothers of term infants, glutamine and glutamic acid were among
the most plentiful free amino acids in the first three months of lactation [45]. Levels of glutamine
increased significantly during the first to the third month of lactation [45,46]. In addition, breast milk,
which contains higher concentrations of glutamine, amongst other free amino acids, is associated with
more rapid weight gain [46] and increased length [47] in the infant. Glutamine also holds a relevant role
in maintaining gut barrier integrity. For example, glutamine augments the effects of growth factors and
influences cell signaling pathways involved in intestinal cell proliferation and differentiation, as well
as the expression of tight junctions [48,49]. Glutamine has also exhibited anti-apoptotic properties in
intestinal cells, attributed to its role in the production of glutathione [48,49].
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Neonates deficient in circulating amino acids such as glutamine and arginine, are associated with
a higher risk of NEC development [50]. In a neonatal rat model of NEC, pups receiving exogenous
administration of glutamine had reduced pathology injury scores and reduced ileal mRNA expression
of the innate immune receptors, Toll-like receptor (TLR)-2 and TLR-4 [51]. As TLR-2 and TLR-4
have established roles in inducing synthesis of inflammatory mediators and increasing apoptosis
in NEC [52–54], their reduced expression by glutamine supplementation suggests a mechanism by
which it mediates protection. In a small study that evaluated the outcomes of arginine and glutamine
supplementation in 25 preterm neonates of less than 34 weeks’ gestation, there were no infants that
developed NEC in the glutamine group and no difference in the NEC incidence in the arginine
group [55]. However, large RCTs of infants diagnosed with severe gastrointestinal disease, including
NEC, spontaneous intestinal perforation, and intestinal structural anomalies, did not show a decreased
risk of death or severe infections while receiving enteral glutamine [56]. Additional large RCTs
evaluating glutamine supplementation in preterm infants did not show a benefit in decreasing the
risk of death, intestinal disease, or long term developmental outcomes [57]. Therefore, despite the
significant levels of glutamine in human breast milk, there is insufficient evidence for exogenous
supplementation of glutamine as a preventative strategy for NEC at this time.
3. Breast Milk and Immune Homeostasis
3.1. Cellular Mechanisms
There are two primary pathways for maternal cellular transfer to the infant—placental transmission
and oral transmission through breastfeeding [58]. Breast milk leukocytes, including macrophages
and neutrophils, survive passage through the neonatal gastrointestinal tract and translocate to blood,
lymph nodes, spleen, and liver [11,58,59]. Understanding the physiological significance of the transfer
of human milk cells to neonates can provide insight into the protective properties of breast milk on the
infant recipient.
The progression through maturational stages of lactation involves alterations in breast milk
leukocyte composition and concentration. In an analysis of CD45+ leukocytes in breast milk, colostrum
contained the highest number of leukocytes compared with transitional milk (8–12 days postpartum)
and mature milk (26–30 days postpartum) [60]. The infant’s gestational age at birth is also associated
with changing concentrations of certain types of breast milk leukocytes. Colostrum contains lower
levels of non-cytotoxic T cells and B lymphocytes with increased gestational age whereas mature milk
of preterm mothers contains lower cytotoxic T cell and natural killer (NK) cell levels when compared to
term milk [60]. In seeking to understand the impact of maternal milk leukocytes on the breastfeeding
infant, Cabinian and colleagues used a murine model to examine the transport and survival of maternal
breast milk leukocytes, primarily T cells, to the gastrointestinal Peyer’s patches of the suckling pup [61].
The observed transfer of cells to the Peyer’s patches implicates the role of breast milk leukocytes
in neonatal intestinal development and localized immunological maturation. The overall relevance
of the differences in human milk cellular content and transfer on the development of NEC requires
further study.
Additionally, maternal and infant bacterial infections influenced concentrations of breast milk
leukocytes and cytokines, notably macrophages and TNF-α levels [11,62]. Maternal infection can
induce a significant leukocyte surge that ranges from 0.7% to 93.6% of total cells in breast milk [11].
A smaller increase in breast milk leukocytes has been observed when the breastfeeding infant develops
an infection [11]. Riskin and colleagues identified that macrophages, as well as neutrophils, comprise
the majority of breast milk leukocytes in mothers with a sick infant [62]. The increase in breast milk
leukocytes in response to an inflammatory process in the mother/infant dyad suggests a dynamic
interaction between maternal and infant immune systems and further supports the benefits of
breast milk.
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3.2. Cytokines
Preterm infants, when compared with their term counterparts, exhibit immune immaturity, which
includes lower production of cytokines and other immunological proteins during challenge with an
inflammatory insult [59]. The presence of cytokines in breast milk provides passive protection and
immune modulation in the infant recipient and results in absorption into the systemic circulation.
In particular, these cytokines include IL-1, IL-2, IL-6, IL-8, IL-10, interferon (IFN)-γ, and TNF-α (Table 1).
Breast milk produced by mothers of full-term infants contains high levels of IL-2, IL-8, and IL-10,
with levels decreasing drastically by day 21 of lactation. In contrast, mothers of preterm infants
have significantly lower levels of cytokines in the colostrum when compared to mothers of full-term
infants [63].
Table 1. Cytokines present in human breast milk and physiologic relevance to the infant.
Cytokine Composition in Human Milk and Significance References
Interleukin (IL)-1
- Human milk IL-1β attenuates the activation of pro-inflammatory
IL-8 and suppresses pro-inflammatory responses of nuclear factor
kappa beta (NF-kB) signaling.
[53,64]
IL-2
- Highest in concentration in colostrum and reduced in later stages
of lactation.
- Recruits T cells to stimulate an antigen-specific immune response.
[63,65,66]
IL-6
- Detected in higher levels in term breast milk.
- Pro-inflammatory properties and is present in the acute phase
of infection.
- Colostrum may contain anti-IL-6 antibodies that cause decreased
immunoglobulin A (IgA) production by breast milk leukocytes.
[63,67,68]
IL-8
- Decreased levels of detection in later stages of lactation.
- Provides chemotactic response of neutrophils.
- Recombinant IL-8 may improve the viability of intestinal cells
when exposed to injury.
[63,69,70]
IL-10
- Maintains anti-inflammatory mechanisms involving limiting the
Th1 response, inhibiting production of inflammatory cytokines,
and promoting immunoglobulin synthesis.
[71–75]
IFN-γ
- Detected in decreasing levels with later stages of lactation.
- Increases activation of intestinal macrophages and is present in
higher concentrations in the ileum of infants with necrotizing
enterocolitis (NEC).
- Pro-inflammatory mechanism of action may provide an infant
with defense against inflammation and infection.
[76–79]
TNF-α
- Detected in decreased levels in colostrum of preterm milk.
- Present in breast milk in association with its soluble receptor,
reducing its pro-inflammatory activity.
[63,80,81]
High levels IL-1RA, an IL-1 receptor, have been detected in breast milk [64]. IL-1β is a member of
the IL-1 family and is known to induce an endogenous innate inflammatory response in enterocytes,
upregulate expression of pro-inflammatory IL-8, and stimulate the nuclear factor kappa beta (NF-kB)
pathway. However, human milk has demonstrated the ability to attenuate the IL-1β-dependent
activation of IL-8 [64]. The protective effects of breast milk on suppressing this NF-kB-mediated
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pro-inflammatory immune response has been shown in intestinal epithelial cells both in vitro and
in vivo, providing evidence of a mechanism mediating protection against NEC development [53,64].
Neonates have a known deficiency in the production of IL-2, which is a necessary cytokine in
the recruitment of T cells required to produce an antigen-specific immune response [65,66]. Human
milk, therefore, provides an ideal source of IL-2 for the newborn. Levels of aqueous IL-2 in human
milk are of highest concentration in colostrum with reduced levels in later stages of lactation [63,65].
The presence of IL-2 in breast milk, which is absorbed by the gastrointestinal tract of the infant, may
enter the systemic circulation to influence the maturing immune system.
IL-6 is a pro-inflammatory cytokine in the acute phase of the inflammatory response [59]. Multiple
studies have observed high levels of IL-6 in colostrum [63,67,68]. An early analysis of IL-6 in breast
milk showed that the presence of an anti-IL-6 antibody in colostrum caused decreased production of
IgA by mononuclear leukocytes, suggesting a relationship between IL-6 and IgA production in breast
milk [67]. Ustundag and colleagues noted higher levels of breast milk IL-6 at two weeks postpartum in
mothers of term infants when compared to milk from mothers of preterm infants [63]. The prevalence
of IL-6 in breast milk with uptake by the infant recipient may have a significant biologic role in neonatal
immune homeostasis.
IL-8 expression by macrophages, endothelial cells, and epithelial cells provides chemotactic activity
for a neutrophil-dependent response to acute inflammation, such as in sepsis and NEC. A decline
in IL-8 levels in breast milk occurs with the advancement in lactational stage [69,70]. Although one
study found no difference in breast milk IL-8 expression in mothers of infants of different gestational
ages [63], others have identified higher IL-8 levels in the breast milk of mothers of preterm infants [69].
Maheshwari and colleagues showed that fetal and adult human intestinal cells treated with recombinant
IL-8 in vitro had increased cell proliferation and differentiation [69]. Additionally, intestinal cells
exposed to injury in vitro demonstrated increased viability when treated with recombinant IL-8 [69].
Thus, the dynamic effects of IL-8 on the developing intestine suggests its physiologic role in intestinal
development as a component of human breast milk.
The anti-inflammatory properties of IL-10 attenuate the immune response to an infection
and maintain tissue homeostasis by inhibition of the activity of Th1 effector cells, NK cells, and
macrophages [71,72]. IL-10 can inhibit the production of inflammatory IL-1, IL-6, IL-8, and TNF-α [72,73].
One study found IL-10 in the aqueous and non-aqueous phases of human milk, with concentrations
found to be highest within the first 24 hours of lactation [72]. IL-10 in breast milk affects the infant by
attracting CD8+ T lymphocytes [72,74] and promoting immunoglobulin synthesis by B cells [72,75].
IFN-γ is a pro-inflammatory cytokine found in human milk in low concentrations with decreasing
levels in the months following birth [76]. IFN-γ is secreted by activated T cells and NK cells and
enhances intestinal macrophage activation [76]. IFN-γ is involved in the signaling pathways that
increase intestinal epithelial barrier permeability [77] and is also detected in higher concentrations in the
ileum of patients with NEC [78]. As infants have a reduced ability to produce IFN-γ due to an immature
immune system [79], breast milk may provide the infant with IFN-γ and other pro-inflammatory
cytokines needed to produce a host defense response against inflammation or infection.
Neonates are deficient in the production of the pro-inflammatory cytokine TNF-α and its receptors,
TNF-α receptor I and II, increasing susceptibility to infection due to immune cell dysregulation.
TNF-α is produced by a variety of immune cell types, including granulocytes and CD4+ lymphocytes.
TNF-α, as an endogenous pyrogen, contributes to systemic inflammation and immune cell regulation.
One study quantified the amount of detectable TNF-α in breast milk and colostrum and identified the
majority of TNF-α to be in association with its soluble receptor [80]. The low amount of unbound TNF-α
in breast milk was theorized to decrease TNF-α pro-inflammatory bioactivity [80]. Two additional
studies have identified a significantly decreased amount of TNF-α in colostrum of mothers who
delivered very preterm (less than 30 weeks’ gestation) when compared to term and preterm groups,
suggesting one reason why preterm infants have increased susceptibility to infection and impaired
immunity [63,81].
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Overall, the evidence suggests that infants, particularly those born preterm, have insufficient
ability to mount an adequate immunological defense due to reduced production of a variety of
cytokines. Breast milk can therefore supplement infants with maternal cytokines that may provide
immune benefits in the protection against neonatal inflammatory diseases such as NEC.
3.3. Nitric Oxide
Nitric oxide (NO) is a soluble molecule produced by isoforms of NO synthase (NOS) and serves
as a potent vasodilator and neurotransmitter at low, physiologic levels [82,83]. Infants derive NO from
dietary sodium nitrite, which is then converted to NO within the gastrointestinal tract by commensal
microbes [82,83]. NO is present in breast milk, as shown in an analysis of healthy lactating mothers
evaluating the concentration of breast milk nitric oxide concentration on postpartum days one through
five [84]. Exclusively breastfeeding mothers had significantly higher nitric oxide concentrations in
their milk, compared with milk expressed from mothers who decided to exclusively formula-feed
their infant [84]. It was theorized that infant suckling activates NOS within the mammary gland with
subsequent secretion of NO into breast milk, which then confers protection to the intestine of the infant
through regulation of intestinal blood flow and maintenance of vascular tone [84].
The upregulation of inducible NOS (iNOS) in response to the release of cytokines and growth
factors has been implicated in NEC pathogenesis [82,85]. During inflammation, high levels of NO, and
its derivative peroxynitrite, contribute to epithelial damage and the disruption of the integrity of the
intestinal barrier [82]. To study abnormal NOS signaling in NEC, Yazji and colleagues used a murine
model of NEC and selectively deleted endothelial TLR-4 expression, which subsequently resulted
in impaired microvascular intestinal perfusion, increased severity of NEC, and reduced endothelial
NOS (eNOS) expression [86]. Additionally, as compared with commercial formula, breast milk was
identified to have higher levels of sodium nitrate, which serves as a precursor for nitrite and nitric
oxide. Enteral administration of exogenous sodium nitrate was associated with decreased severity of
NEC and improved intestinal perfusion [86]. Overall, these results suggest the protective role of breast
milk in augmenting physiologic nitrate-nitrite-NO signaling to improve intestinal vascular perfusion
and protect against intestinal barrier disruption in NEC.
4. Summary
Human breast milk contains a dynamic diversity of bioactive components needed for infant
growth, immune homeostasis, and intestinal maturation. The composition of human milk varies
with the stage of lactation, gestational age of the infant, the health of the mother/infant dyad, and
the nutritional status of the mother. The dietary intake of the breastfeeding mother has been shown
to influence the variability of human milk concentrations of fat-soluble and water-soluble vitamins
and other nutrients. These nutrients, including immunoglobulins, growth factors, cytokines, and
immune cells, have been demonstrated to transfer from the mother to the neonate through breast
milk [87,88]. The ability of these components to regulate intestinal cell proliferation and differentiation
as well as influence gut microbial colonization emphasizes the protective role of breast milk in
infant metabolism and neurodevelopment, intestinal microbial homeostasis, and protection against
NEC [87,88]. The growing field of research studying the outcomes related to breastfeeding reinforces
the immunological value of breast milk on infant nutrition and protection from inflammatory disorders
such as NEC.
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